US Patent

US8637512 — Formulations and method of treatment

Formulation · Assigned to Glaxo Group Ltd · Expires 2029-01-07 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a sustained release formulation of lamotrigine, the active ingredient in Lamictal, and methods of treatment and uses thereof.

USPTO Abstract

A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US8637512
Jurisdiction
US
Classification
Formulation
Expires
2029-01-07
Drug substance claim
No
Drug product claim
Yes
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.